Skip to content

Rapport Therapeutics, Inc. RAPP Book value per share

Book value per share at other companies

Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$18.68+1.2%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$15.32+71.2%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$48.82+134%
Biohaven logo
BiohavenBHVN
$0.88-65.5%
Septerna, Inc. logo
Septerna, Inc.SEPN
$8.46+193%
PVL
Palvella TherapeuticsPVLA
$17.75+252%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s book value per share?
Rapport Therapeutics, Inc. (RAPP) reported book value per share of $9.98 in Q1 2026.
How has Rapport Therapeutics, Inc.'s book value per share changed year-over-year?
Rapport Therapeutics, Inc.'s book value per share increased by 23.2% year-over-year, from $8.11 to $9.98.
What is the long-term trend for Rapport Therapeutics, Inc.'s book value per share?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s book value per share has grown at a -14.5% compound annual growth rate (CAGR), from -$17.02 to $12.45.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.